Oncolytics Biotech (NASDAQ:ONCY) CEO Jared Kelly Purchases 29,500 Shares

Oncolytics Biotech Inc. (NASDAQ:ONCY) CEO Jared Kelly bought 29,500 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The stock was bought at an average price of $0.84 per share, for a total transaction of $24,780.00. Following the acquisition, the chief executive officer directly owned 109,000 shares of the company’s stock, valued at $91,560. The trade was a 37.11% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Jared Kelly also recently made the following trade(s):

• On Wednesday, February 11th, Jared Kelly bought 5,600 shares of Oncolytics Biotech stock. The stock was purchased at an average cost of $0.84 per share, for a total transaction of $4,704.00.

Oncolytics Biotech Stock Up 27.0%

Oncolytics Biotech stock opened at $1.06 on Friday. The business has a 50-day simple moving average of $0.98 and a two-hundred day simple moving average of $1.07. Oncolytics Biotech Inc. has a 52-week low of $0.33 and a 52-week high of $1.51. The company has a market cap of $112.52 million, a P/E ratio of -3.79 and a beta of 0.99.

Oncolytics Biotech (NASDAQ:ONCY) last announced its earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. Research analysts anticipate that Oncolytics Biotech Inc. will post -0.28 EPS for the current fiscal year.

More Oncolytics Biotech News

Here are the key news stories impacting Oncolytics Biotech this week:

• Positive Sentiment: Director Patricia S. Andrews bought 35,400 shares at $0.86 (raising her stake 82.85% to 78,128 shares). SEC Filing
• Positive Sentiment: Insider Andrew Aromando purchased 29,600 shares at $0.86 (increasing his position 116.08% to 55,100 shares). SEC Filing
• Positive Sentiment: Director Bernd R. Seizinger acquired a total of 100,000 shares across Feb. 11–12 (60k at $0.83 and 40k at $0.85), boosting his holdings to ~566,991 shares. SEC Filing
• Positive Sentiment: VP Allison Hagerman bought 10,000 shares at $0.83 (raising her stake ~9.5% to 115,059 shares). SEC Filing
• Positive Sentiment: Director Deborah M. Brown purchased 25,000 shares at $0.85 (a ~29.5% increase; now ~109,851 shares). SEC Filing
• Positive Sentiment: Insider Thomas C. Heineman bought 12,132 shares at $0.83 (increasing to ~282,818 shares). SEC Filing
• Positive Sentiment: Director Wayne Pisano purchased 30,000 shares at $0.84 (raising his stake ~6.5% to ~492,414 shares). SEC Filing
• Positive Sentiment: CFO Kirk Look bought 12,000 shares at $0.84 (increasing to ~287,515 shares). SEC Filing
• Positive Sentiment: CEO Jared Kelly purchased a total of 35,100 shares across Feb. 11–12 at ~$0.84 (bringing his holdings to ~109,000 shares, a ~37% increase). SEC Filing

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Scientech Research LLC purchased a new position in Oncolytics Biotech during the 3rd quarter valued at approximately $25,000. Security National Bank of Sioux City Iowa IA purchased a new position in shares of Oncolytics Biotech in the fourth quarter valued at $29,000. Ground Swell Capital LLC bought a new stake in Oncolytics Biotech in the fourth quarter worth $30,000. CIBC Private Wealth Group LLC purchased a new stake in Oncolytics Biotech during the fourth quarter valued at $44,000. Finally, Tocqueville Asset Management L.P. bought a new position in Oncolytics Biotech during the fourth quarter valued at $63,000. Institutional investors own 6.82% of the company’s stock.

Analysts Set New Price Targets

ONCY has been the subject of a number of analyst reports. Wall Street Zen cut Oncolytics Biotech from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Oncolytics Biotech in a report on Monday, December 29th. HC Wainwright lifted their price target on shares of Oncolytics Biotech from $5.00 to $10.00 and gave the company a “buy” rating in a report on Monday, November 17th. Finally, Zacks Research upgraded shares of Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 17th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Oncolytics Biotech currently has a consensus rating of “Moderate Buy” and an average target price of $6.25.

About Oncolytics Biotech

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.